Key points are not available for this paper at this time.
Right on target: A chemically defined vascular-targeting antibody–drug conjugate (ADC) that offers comprehensive tumor coverage has been developed. When injected intravenously, this ADC potently inhibited tumor growth in a syngeneic immunocompetent model of murine cancer which cannot be cured by conventional cytotoxic agents. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Bernardes et al. (Thu,) studied this question.